Trends In Insulin Therapy Acceptance In India

An eight-city physician survey in India has thrown up some interesting findings on diabetes treatment approaches in the country, including that a significant percentage of physicians shift patients managed on oral therapies to insulin within three years largely because of poor glycemic control.

An eight-city physician survey in India has thrown up some interesting findings on diabetes treatment approaches in the country, including that a significant percentage of physicians shift patients managed on oral therapies to insulin within three years largely because of poor glycemic control.

More from Alimentary/Metabolic

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

 

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By 

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

More from Therapy Areas